Pharmaron has signed a multi-year agreement with AstraZeneca to accelerate drug discovery by supporting the Medicines Units.
Pursuant to the agreement, Pharmaron will offer discovery services in the areas of chemistry, drug metabolism and pharmacokinetics (DMPK), and efficacy screening to AstraZeneca. Financial details of the deal were not revealed.
AstraZeneca collaboration sponsor and iMed infection head Manos Perros said, "Pharmaron scientists will be integrated into our project teams and play an important role in helping us fulfill our commitment to delivering meaningful medicines to patients worldwide."
A team of scientists in research laboratories located in Pharmaron's drug discovery service center in Beijing will conduct the services.
The availability of screening and chemistry services at a single partner is estimated to assist AstraZeneca in the drug discovery programs.
Pharmaron chairman and CEO Dr. Boliang Lou said, "This partnership is an important milestone for Pharmaron as we are strengthening our capacity in the area of fully integrated services as a highly competitive and global player."